Asymchem Laboratories (Tianjin) Co., Ltd. (06821.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

24.7x

Market Cap

HKD 48.47B

MomentumView details →

1D Return

+0.00%

YTD Return

+87.92%

RSI (14)

58.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

24.7x

Market Cap

HKD 48.47B

RSI (14)

58.6

MomentumView details →

1D Return

+0.00%

YTD Return

+87.92%

ProfitabilityView details →

Gross Margin

40.51%

Net Margin

14.67%

EBITDA Margin

20.34%

ROE (TTM)

5.83%

ROA (TTM)

4.93%

Asset Turnover

0.34x

GrowthView details →

Revenue YoY

+11.99%

EPS YoY

−1.69%

FCF YoY

−7.31%

Revenue CAGR 3Y

−13.36%

EPS CAGR 3Y

−29.28%

EBITDA YoY

+14.47%

EarningsView details →

EPS (Actual)

HKD 0.35

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

HKD 0.00

Avg Surprise (4Q)

—

Rev Surprise

−6.71%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

4.56x

Quick Ratio

3.76x

Div Yield

1.12%

Div Rate

HKD 1.50

Div Growth 1Y

+24.39%

Financials snapshotView financials →

Revenue (TTM)

7.05B

Net Income (TTM)

1.03B

Op. CF (TTM)

1.59B

Next earningsNov 4, 2026 →

Latest newsMore news →

Asymchem Laboratories announced its first-half 2026 results: revenue of 3.607 billion yuan, up 13.13% year-on-year, and net profit attributable to shareholders of 520 million yuan, down 15.71% from 617 million yuan in the same period of 2025.11d ago

Chinese innovative drug and CXO stocks rebounded strongly, with the CSI Innovative Drug Industry Index rising 28.04% since June 9, 2026, and several stocks hitting daily limits on August 7, 2026.28d ago

Similar companies

艾力斯688578.SH GeneOne Life Science, Inc.011000.KS Pharmaron Beijing Co., Ltd.03759.HK RemeGen Co., Ltd.09995.HK Revolution Medicines, Inc.RVMD Amicogen, Inc.092040.KQ Find similar companies →

Latest newsMore news →

Asymchem Laboratories announced its first-half 2026 results: revenue of 3.607 billion yuan, up 13.13% year-on-year, and net profit attributable to shareholders of 520 million yuan, down 15.71% from 617 million yuan in the same period of 2025.11d ago Chinese innovative drug and CXO stocks rebounded strongly, with the CSI Innovative Drug Industry Index rising 28.04% since June 9, 2026, and several stocks hitting daily limits on August 7, 2026.28d ago